HGF/c-MET axis in tumor microenvironment and metastasis formation

Biomedicines

Volumn 3, Issue 1, 2015, Pages 71-88

  Spina, Anna ^a   De Pasquale, Valeria ^a   Cerulo, Giuliana ^a   Cocchiaro, Pasquale ^a   Morte, Rossella Della ^a   Avallone, Luigi ^a   Pavone, Luigi Michele ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

C MET; Cancer; HGF; Metastasis; Microenvironment

Indexed keywords

EID: 84991359260     PISSN: None     EISSN: 22279059     Source Type: Journal    
DOI: 10.3390/biomedicines3010071     Document Type: Review

References (112)

1. Fidler, I.J. Critical determinants of metastasis. Semin. Cancer Biol. 2002, 12, 89-96
2. Geiger, T.R.; Peeper, D.S. Metastasis mechanisms. Biochim. Biophys. Acta 2009, 1796, 293-308
3. Zigrino, P.; Löffek, S.; Mauch, C. Tumor-stroma interactions: their role in the control of tumor cell invasion. Biochimie 2005, 87, 321-328
4. Langley, R.R.; Fidler, I.J. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr. Rev. 2007, 28, 297-321
5. Hu, M.; Polyak, K. Microenvironmental regulation of cancer development. Curr. Opin. Genet. Dev. 2008, 18, 27-34
6. Egeblad, M.; Rasch, M.G.; Weaver, V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell. Biol. 2010, 22, 697-706
7. Bremnes, R.M.; Dønnem, T.; Al-Saad, S.; Al-Shibli, K.; Andersen, S.; Sirera, R.; Camps, C.; Marinez, I.; Busund, L.T. The role of tumor stroma in cancer progression and prognosis: Emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J. Thorac. Oncol. 2011, 6, 209-217
8. Friedl, P.; Alexander, S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011, 147, 992-1009
9. Matsumoto, M.; Nakamura, T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J. Cancer 2006, 119, 477-483
10. Lesko, E.; Majka, M. The biological role of HGF-MET axis in tumor growth and development of metastasis. Front. Biosci. 2008, 13, 1271-1280
11. Steffan, J.J.; Coleman, D.T.; Cardelli, J.A. The HGF-Met signaling axis: emerging themes and targets of inhibition. Curr. Protein Pept. Sci. 2011, 12, 12-22
12. Matsumoto, K.; Date, K.; Ohmichi, H.; Nakamura, T. Hepatocyte growth factor in lung morphogenesis and tumor invasion: Role as a mediator in epithelium-mesenchyme and tumor-stroma interactions. Cancer Chemother. Pharmacol. 1996, 38, S42-S47
13. Nakamura, T.; Matsumoto, K.; Kiritoshi, A.; Tano, Y.; Nakamura, T. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: In vitro analysis of tumor-stromal interactions. Cancer Res. 1997, 57, 3305-3313
14. Weidner, K.M.; Sachs, M.; Birchmeier, W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell Biol. 1993, 121, 145-154
15. Weimar, I.S.; de Jong, D.; Muller, E.J.; Nakamura, T.; van Gorp, J.M.; de Gast, G.C.; Gerritsen, W.R. Hepatocyte growth factor/scatter factor promotes adhesion of lymphoma cells to extracellular matrix molecules via alpha 4 beta 1 and alpha 5 beta 1 integrins. Blood 1997, 89, 990-1000
16. Elliott, B.E.; Hung, W.L.; Boag, A.H.; Tuck, A.B. The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer. Can. J. Physiol. Pharmacol. 2002, 80, 91-102
17. Gao, C.F.; Vande Woude, G.F. HGF/SF-Met signaling in tumor progression. Cell. Res. 2005, 15, 49-51
18. Accornero, P.; Miretti. S.; Cucuzza, L.S.; Martignani, E.; Baratta, M. Epidermal growth factor and hepatocyte growth factor cooperate to enhance cell proliferation, scatter, and invasion in murine mammary epithelial cells. J. Mol. Endocrinol. 2010, 44, 115-125
19. Ogunwobi, O.O.; Liu, C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin. Exp. Metastasis 2011, 28, 721-731
20. Pavone, L.M.; Cattaneo, F.; Rea, S.; de Pasquale, V.; Spina, A.; Sauchelli, E.; Mastellone, V.; Ammendola, R. Intracellular signaling cascades triggered by the NK1 fragment of hepatocyte growth factor in human prostate epithelial cell line PNT1A. Cell Signal. 2011, 23, 1961-1971
21. Varkaris, A.; Corn, P.G.; Gaur, S.; Dayyani, F.; Logothetis, C.J.; Gallick, G.E. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin. Investig. Drugs 2011, 20, 1677-1684
22. Tanahashi, T.; Osada, S.; Yamada, A.; Kato, J.; Yawata, K.; Mori, R.; Imai, H.; Sasaki, Y.; Saito, S.; Tanaka, Y.; et al. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition. Int. J. Oncol. 2013, 42, 556-564
23. Benvenuti, S.; Comoglio, P.M. The MET receptor tyrosine kinase in invasion and metastasis. J. Cell Physiol. 2007, 213, 316-325
24. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 2003, 4, 915-925
25. Matsumoto, K.; Okazaki, H.; Nakamura, T. Novel function of prostaglandins as inducers of gene expression of HGF and putative mediators of tissue regeneration. J. Biochem. 1995, 117, 458-464
26. Apte, R.N.; Voronov, E. Interleukin-1-A major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 2002, 12, 277-290
27. Xouri, G.; Christian, S. Origin and function of tumor stroma fibroblasts. Semin. Cell Dev. Biol. 2010, 21, 40-46
28. Räsänen, K.; Vaheri, A. Activation of fibroblasts in cancer stroma. Exp. Cell Res. 2010, 316, 2713-2722
29. Wu, X.; Chen, X.; Zhou, Q.; Li, P.; Yu, B.; Li, J.; Qu, Y.; Yan, J.; Yu, Y.; Yan, M.; et al. Hepatocyte growth factor activates tumor stromal fibroblasts to promote tumorigenesis in gastric cancer. Cancer Lett. 2013, 335, 128-135
30. Jia, C.C.; Wang, T.T.; Liu, W.; Fu, B.S.; Hua, X.; Wang, G.Y.; Li, T.J.; Li, X.; Wu, X.Y.; Tai, Y.; et al. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS One 2013, 8, e63243
31. Dunn, K.L.; Espino, P.S.; Drobic, B.; He, S.; Davie, J.R. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem. Cell Biol. 2005, 83, 1-14
32. Egeblad, M.; Littlepage, L.E.; Werb, Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb. Symp. Quant. Biol. 2005, 70, 383-388
33. Forst, B.; Hansen, M.T.; Klingelhöfer, J.; Møller, H.D.; Nielsen, G.H.; Grum-Schwensen, B.; Ambartsumian, N.; Lukanidin, E.; Grigorian, M. Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice. PLoS One 2010, 5, e10374
34. Bao, B.; Thakur, A.; Li, Y.; Ahmad, A.; Azmi, A.S.; Banerjee, S.; Kong, D.; Ali, S.; Lum, L.G.; Sarkar, F.H. The immunological contribution of NF-κB within the tumor microenvironment: A potential protective role of zinc as an anti-tumor agent. Biochim. Biophys. Acta 2012, 1825, 160-172
35. Vitale, M.; Cantoni, C.; Pietra, G.; Mingari, M.C.; Moretta, L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur. J. Immunol. 2014, 44, 1582-92
36. Mishra, P.; Banerjee, D.; Ben-Baruch, A. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J. Leukoc. Biol. 2011, 89, 31-39
37. Wei, J.J.; Song, C.W.; Sun, L.C.; Yuan, Y.; Li, D.; Yan, B.; Liao, S.J.; Zhu, J.H.; Wang, Q.; Zhang, G.M.; et al. SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells. Cancer Immunol. Immunother. 2012, 61, 303-312
38. Rigoni, A.; Colombo, M.P.; Pucillo, C. The role of mast cells in molding the tumor microenvironment. Cancer Microenviron. 2014, doi:10.1007/s12307-014-0152-8
39. Suffee, N.; Richard, B.; Hlawaty, H.; Oudar, O.; Charnaux, N.; Sutton, A. Angiogenic properties of the chemokine RANTES/CCL5. Biochem. Soc. Trans. 2011, 39, 1649-1653
40. Lakshmi Narendra, B.; Eshvendar Reddy, K.; Shantikumar, S.; Ramakrishna, S. Immune system: A double-edged sword in cancer. Inflamm. Res. 2013, 62, 823-834
41. Becker, Y. Molecular immunological approaches to biotherapy of human cancers-A review, hypothesis and implications. Anticancer Res. 2006, 26, 1113-1134
42. Lukanidin, E.; Sleeman, J.P. Building the niche: the role of the S100 proteins in metastatic growth. Semin. Cancer Biol. 2012, 22, 216-225
43. Bettum, I.J.; Vasiliauskaite, K.; Nygaard, V.; Clancy, T.; Pettersen, S.J.; Tenstad, E.; Maelandsmo, G.M.; Prasmickaite, L. Metastasis-associated protein S100A4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Lett. 2014, 344, 28-39
44. Shinkaruk, S.; Bayle, M.; Laïn, G.; Déléris, G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr. Med. Chem. Anticancer Agents 2003, 3, 95-117
45. Doucet, C.; Jasmin, C.; Azzarone, B. Unusual interleukin-4 and-13 signaling in human normal and tumor lung fibroblasts. Oncogene 2000, 19, 5898-5905
46. Pickup, M.; Novitskiy, S.; Moses, H.L. The roles of TGFβ in the tumour microenvironment. Nat. Rev. Cancer 2013, 13, 788-799
47. Adurthi, S.; Mukherjee, G.; Krishnamurthy, H.; Sudhir, K.; Bafna, U.D.; Umadevi, K.; Jayshree, R.S. Functional tumor infiltrating TH1 and TH2 effectors in large early-stage cervical cancer are suppressed by regulatory T cells. Int. J. Gynecol. Cancer 2012, 22, 1130-1137
48. Alizadeh, D.; Larmonier, N. Chemotherapeutic targeting of cancer-induced immunosuppressive cells. Cancer Res. 2014, 74, 2663-2668
49. Mekori, Y.A.; Hershko, A.Y. T cell-mediated modulation of mast cell function: Heterotypic adhesion-induced stimulatory or inhibitory effects. Front. Immunol. 2012, 30, 3-6
50. Younos, I.; Donkor, M.; Hoke, T.; Dafferner, A.; Samson, H.; Westphal, S.; Talmadge, J. Tumorand organ-dependent infiltration by myeloid-derived suppressor cells. Int. Immunopharmacol. 2011, 11, 816-826
51. Sanz-Moreno, V.; Gaggioli, C.; Yeo, M.; Albrengues, J.; Wallberg, F.; Viros, A.; Hooper, S.; Mitter, R.; Féral, C.C.; Cook, M.; et al. ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma. Cancer Cell. 2011, 20, 229-245
52. Wolf, K.; Wu, Y.I.; Liu, Y.; Geiger, J.; Tam, E.; Overall, C.; Stack, M.S.; Friedl, P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9, 893-904
53. Hidalgo-Carcedo, C.; Hooper, S.; Chaudhry, S.I.; Williamson, P.; Harrington, K.; Leitinger, B.; Sahai, E. Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. Nat. Cell. Biol. 2011, 13, 49-58
54. Weidert, E.; Pohler, S.E.; Gomez, E.W.; Dong, C. Actinomyosin contraction, phosphorylation of VE-cadherin, and actin remodeling enable melanoma-induced endothelial cell-cell junction disassembly. PLoS One 2014, 9, e108092
55. Park, Y.M.; Yoo, S.H.; Kim, S.H. Adipose-derived stem cells induced EMT-like changes in H358 lung cancer cells. Anticancer Res. 2013, 33, 4421-4430
56. Eterno, V.; Zambelli, A.; Pavesi, L.; Villani, L.; Zanini, V.; Petrolo, G.; Manera, S.; Tuscano, A.; Amato, A. Adipose-derived Mesenchymal Stem Cells (ASCs) may favour breast cancer recurrence via HGF/c-Met signaling. Oncotarget 2014, 5, 613-633
57. Jedeszko, C.; Victor, B.C.; Podgorski, I.; Sloane, B.F. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Research 2009, 69, 9148-9955
58. Sung, K.E.; Su, X.; Berthier, E.; Pehlke, C.; Friedl, A.; Beebe, D.J. Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models. PLoS One 2013, 8, e76373
59. Vermeulen, L.; de sousa, e.; melo, f.; van der Heijden, M.; Cameron, K.; de Jong, J.H.; Borovski, T.; Tuynman, J.B.; Todaro, M.; Merz, C.; et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12, 468-476
60. Todaro, M.; Gaggianesi, M.; Catalano, V.; Benfante, A.; Iovino, F.; Biffoni, M.; Apuzzo, T.; Sperduti, I.; Volpe, S.; Cocorullo, G.; et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell. 2014, 14, 342-356
61. Vermeulen, L.; Snippert, H.J. Stem cell dynamics in homeostasis and cancer of the intestine. Nat Rev Cancer. 2014, 14, 468-480
62. Trusolino, L.; Bertotti, A.; Comoglio, P.M. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001, 107, 643-654
63. Chen, S.Y.; Chen, H.C. Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion. Mol. Cell. Biol. 2006, 26, 5155-5167
64. Ghatak, S.; Hascall, V.C.; Markwald, R.R.; Misra, S. Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J. Biol. Chem. 2010, 285, 19821-19832
65. Orian-Rousseau, V.; Chen, L.; Sleeman, J.P.; Herrlich, P.; Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 2002, 16, 3074-3086
66. Recio, J.A.; Merlino, G. Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1. Cancer Res. 2003, 63, 1576-1582
67. Beviglia, L.; Kramer, R.H. HGF induces FAK activation and integrin-mediated adhesion in MTLn3 breast carcinoma cells. Int. J. Cancer. 1999, 83, 640-649
68. Matsumoto, K.; Matsumoto, K.; Nakamura, T.; Kramer, R.H. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem. 1994, 269, 31807-31813
69. Watanabe, T.; Tsuda, M.; Makino, Y.; Ichihara, S.; Sawa, H.; Minami, A.; Mochizuki, N.; Nagashima, K.; Tanaka, S. Adaptor molecule Crk is required for sustained phosphorylation of Grb2-associated binder 1 and hepatocyte growth factor-induced cell motility of human synovial sarcoma cell lines. Mol. Cancer Res. 2006, 4, 499-510
70. Cheng, N.; Chytil, A.; Shyr, Y.; Joly, A.; Moses, H.L. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol. Cancer Res. 2008, 6, 1521-1533
71. Ide, T.; Kitajima, Y.; Miyoshi, A.; Ohtsuka, T.; Mitsuno, M.; Ohtaka K.; Miyazaki, K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol. 2007, 4, 2600-2607
72. Allen, M.; Louise Jones, J. Jekyll and Hyde: The role of the microenvironment on the progression of cancer. J. Pathol. 2011, 223, 162-176
73. Kim, B.W.; Cho, H.; Chung, J.Y.; Conway, C.; Ylaya, K.; Kim, J.H.; Hewitt, S.M. Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. J. Transl. Med. 2013, 11, 185
74. Brahimi-Horn, M.C.; Chiche, J.; Pouysségur, J. Hypoxia and cancer. J. Mol. Med. (Berl). 2007, 85, 1301-1307
75. Sullivan, R.; Graham, C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 2007, 26, 319-331
76. Ide, T.; Kitajima, Y.; Miyoshi, A.; Ohtsuka, T.; Mitsuno, M.; Ohtaka, K.; Koga, Y.; Miyazaki, K. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway. Int. J. Cancer. 2006, 119, 2750-2759
77. Sulpice, E.; Ding, S.; Muscatelli-Groux, B.; Bergé, M.; Han, Z.C.; Plouet, J.; Tobelem, G.; Merkulova-Rainon, T. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol. Cell. 2009, 101, 525-539
78. Cecchi, F.; Rabe, D.C.; Bottaro, D.P. Targeting the HGF/Met signaling pathway in cancer. Eur. J. Cancer 2010, 46, 1260-1270
79. Accornero, P.; Pavone, L.M.; Baratta, M. The scatter factor signaling pathways as therapeutic associated target in cancer treatment. Curr. Med. Chem. 2010, 17, 2699-2712
80. Yap, T.A.; Sandhu, S.K.; Alam, S.M.; de Bono, J.S. HGF/c-MET targeted therapeutics: Novel strategies for cancer medicine. Curr. Drug Targets 2011, 12, 2045-2058
81. Jung, K.H.; Park, B.H.; Hong, S.S. Progress in cancer therapy targeting c-Met signaling pathway. Arch. Pharm. Res. 2012, 35, 595-604
82. Scagliotti, G.V.; Novello, S.; von Pawel, J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat. Rev. 2013, 39, 793-801
83. Smyth, E.C.; Sclafani, F.; Cunningham, D. Emerging molecular targets in oncology: Clinical potential of MET/hepatocyte growth-factor inhibitors. Oncol. Targets Ther. 2014, 7, 1001-1014
84. Traxler, P. Tyrosine kinases as targets in cancer therapy-Successes and failures. Expert Opin. Ther. Targets 2003, 7, 215-234
85. Goldman, J.W.; Laux, I.; Chai, F.; Savage, R.E.; Ferrari, D.; Garmey, E.G.; Just, R.G.; Rosen, L.S. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012, 118, 5903-5911
86. Heigener, D.F.; Reck, M. Crizotinib. Recent Results Cancer Res. 2014, 201, 197-205
87. Eder, J.P.; Shapiro, G.I.; Appleman, L.J.; Zhu, A.X.; Miles, D.; Keer, H.; Cancilla, B.; Chu, F.; Hitchcock-Bryan, S.; Sherman, L.; et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res. 2010, 16, 3507-3516
88. Clinical Trials Involving HGF/SF-Met Inhibitors. Available online: http://www.vai.org/ metclinicaltrials (accessed on 7 January 2015)
89. Takeuchi, S.; Wang W.; Li, Q.; Yamada, T.; Kita, K.; Donev, I.S.; Nakamura, T.; Matsumoto, K.; Shimizu, E.; Nishioka, Y.; et al. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am. J. Pathol. 2012, 181, 1034-1043
90. Awazu, Y.; Nakamura, K.; Mizutani, A.; Kakoi, Y.; Iwata, H.; Yamasaki, S.; Miyamoto, N.; Imamura, S.; Miki, H.; Hori, A. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities. Mol. Cancer Ther. 2013, 12, 913-924
91. Elisei, R.; Schlumberger, M.J.; Müller, S.P.; Schöffski, P.; Brose, M.S.; Shah, M.H.; Licitra, L.; Jarzab, B.; Medvedev, V.; Kreissl, M.C.; et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 2013, 31, 3639-3646
92. Ciamporcero, E.; Miles, K.M.; Adelaiye, R.; Ramakrishnan, S.; Shen, L.; Ku, S.Y.; Pizzimenti, S.; Sennino, B.; Barrera, G.; Pili, R. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol. Cancer Ther. 2014, doi:10.1158/1535-7163.MCT-14-0094
93. Marchion, D.C.; Bicaku, E.; Xiong, Y.; Bou Zgheib, N.; Al Sawah, E.; Stickles, X.B.; Judson, P.L.; Lopez, A.S.; Cubitt, C.L.; Gonzalez-Bosquet, J.; et al. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol. Rep. 2013, 29, 2011-2018
94. Tibes, R.; Fine, G.; Choy, G.; Redkar, S.; Taverna, P.; Oganesian, A.; Sahai, A.; Azab, M.; Tolcher, A.W. A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013, 71, 463-471
95. Qi, W.; Cooke, L.S.; Stejskal, A.; Riley, C.; Croce, K.D.; Saldanha, J.W.; Bearss, D.; Mahadevan, D. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer. BMC Cancer 2009, 9, 142
96. Welsh, J.W.; Mahadevan, D.; Ellsworth, R.; Cooke, L.; Bearss, D.; Stea, B. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat. Oncol. 2009, 4, 69
97. Kim, K.J.; Wang, L.; Su, Y.C.; Gillespie, G.Y.; Salhotra, A.; Lal, B.; Laterra, J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. 2006, 12, 1292-1298
98. Patnaik, G.; Weiss, J.; Papadopoulos, K.; Tibes, R.; Tolcher, A.W.; Payumo, F.C.; Cotreau, M.M.; Jac, J.; Isaacs, R.; Ramanathan, R.K. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J. Clin. Oncology 2010, 28, abstr. 2525
99. Martin, L.P.; Sill, M.; Shahin, M.S.; Powell, M.; DiSilvestro, P.; Landrum, L.M.; Gaillard, S.L.; Goodheart, M.J.; Hoffman, J.; Schilder, R.J. A phase II evaluation of AMG 102 (rilotumumab) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: A gynecologic oncology group study. Gynecol. Oncol. 2014, 132, 526-530
100. Goetsch, L.; Broussas, M.; Fabre-Lafay, S.; Robert, A.; Lepecquet, A.M.; Gonzalez, A.; Wurch, T.; Bailly, C.; Corvaia, N. Abstract 2448: h224G11, a humanized whole antibody targeting the c-Met receptor, induces c-Met down-regulation and triggers ADCC functions. Cancer Res. 2010, doi:10.1158/1538-7445.AM10-2448
101. Spigel, D.R.; Ervin, T.J.; Ramlau, R.A.; Daniel, D.B.; Goldschmidt, J.H., Jr.; Blumenschein, G.R., Jr.; Krzakowski, M.J.; Robinet, G.; Godbert, B.; Barlesi, F.; et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2013, 31, 4105-4114
102. McLarty, J.; Bigelow, R.L.; Smith, M.; Elmajian, D.; Ankem, M.; Cardelli, J.A. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev. Res. 2009, 2, 673-682
103. Mizuno, S.; Nakamura, T. HGF-MET cascade, a key target for inhibiting cancer metastasis: The impact of NK4 discovery on cancer biology and therapeutics. Int. J. Mol. Sci. 2013, 14, 888-919
104. Michieli, P.; Mazzone, M.; Basilico, C.; Cavassa, S.; Sottile, A.; Naldini, L.; Comoglio, P.M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004, 6, 61-73
105. Zhang, Y.; Yang, P.; Wang, X.F. Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell. Biol. 2014, 24, 153-160
106. Chen, F.; Hu, S.J. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: A review. J. Biochem. Mol. Toxicol. 2012, 26, 79-86
107. Reid, J.F.; Sokolova, V.; Zoni, E.; Lampis, A.; Pizzamiglio, S.; Bertan, C.; Zanutto, S.; Perrone, F.; Camerini, T.; Gallino, G.; et al. miRNA profiling in colorectal cancer highlights miR-1 involvement in MET-dependent proliferation. Mol. Cancer Res. 2012, 10, 504-515
108. Mungunsukh, O.; Day, R.M. Transforming growth factor-β1 selectively inhibits hepatocyte growth factor expression via a micro-RNA-199-dependent posttranscriptional mechanism. Mol. Biol. Cell 2013, 24, 2088-2097
109. Xu, J.; Huang, Z.; Lin, L.; Fu, M.; Gao, Y.; Shen, Y.; Zou, Y.; Sun, A.; Qian, J.; Ge, J. miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation. Sci. China Life Sci. 2014, 57, 989-997
110. Yang, X.; Zhang, X.F.; Lu, X.; Jia, H.L.; Liang, L.; Dong, Q.Z.; Ye, Q.H.; Qin, L.X. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-cMet pathway. Hepatology 2014, 59, 1874-1885
111. Wilson, T.R.; Fridlyand, J.; Yan, Y.; Penuel, E.; Burton, L.; Chan, E.; Peng, J.; Lin, E.; Wang, Y.; Sosman, J.; et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 2012, 487, 505-509
112. Straussman, R.; Morikawa, T.; Shee, K.; Barzily-Rokni, M.; Qian, Z.R.; Du, J.; Davis, A.; Mongare, M.M.; Gould, J.; Frederick, D.T.; et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012, 487, 500-504